Clinical Research Directory
Browse clinical research sites, groups, and studies.
Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01
Sponsor: BlueRock Therapeutics
Summary
This is a multicenter study to evaluate the safety and clinical outcomes of BRT-DA01 in subjects with PD who previously received BRT-DA01 in the Phase 1 Study MSK-DA01-101.No investigational therapy will be administered in this study.
Official title: Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01, a Human Embryonic Stem Cell-Derived Midbrain Dopaminergic Neuronal Cell Therapy
Key Details
Gender
All
Age Range
50 Years - 78 Years
Study Type
OBSERVATIONAL
Enrollment
12
Start Date
2023-05-16
Completion Date
2027-09
Last Updated
2024-04-12
Healthy Volunteers
No
Conditions
Locations (3)
University of California, Irvine
Orange, California, United States
Weill Cornell Medical College
New York, New York, United States
Toronto Western Hospital
Toronto, Ontario, Canada